Literature DB >> 30081144

Delivery of immunoglobulin G antibodies to the rat nervous system following intranasal administration: Distribution, dose-response, and mechanisms of delivery.

Niyanta N Kumar1, Jeffrey J Lochhead1, Michelle E Pizzo2, Geetika Nehra1, Sam Boroumand1, Gretchen Greene1, Robert G Thorne3.   

Abstract

The intranasal route has been hypothesized to circumvent the blood-brain and blood-cerebrospinal fluid barriers, allowing entry into the brain via extracellular pathways along olfactory and trigeminal nerves and the perivascular spaces (PVS) of cerebral blood vessels. We investigated the potential of the intranasal route to non-invasively deliver antibodies to the brain 30 min following administration by characterizing distribution, dose-response, and mechanisms of antibody transport to and within the brain after administering non-targeted radiolabeled or fluorescently-labeled full length immunoglobulin G (IgG) to normal adult female rats. Intranasal [125I]-IgG consistently yielded highest concentrations in the olfactory bulbs, trigeminal nerves, and leptomeningeal blood vessels with their associated PVS. Intranasal delivery also resulted in significantly higher [125I]-IgG concentrations in the CNS than systemic (intra-arterial) delivery for doses producing similar endpoint blood concentrations. Importantly, CNS targeting significantly increased with increasing dose only with intranasal administration, yielding brain concentrations that ranged from the low-to-mid picomolar range with tracer dosing (50 μg) up to the low nanomolar range at higher doses (1 mg and 2.5 mg). Finally, intranasal pre-treatment with a previously identified nasal permeation enhancer, matrix metalloproteinase-9, significantly improved intranasal [125I]-IgG delivery to multiple brain regions and further allowed us to elucidate IgG transport pathways extending from the nasal epithelia into the brain using fluorescence microscopy. The results show that it may be feasible to achieve therapeutic levels of IgG in the CNS, particularly at higher intranasal doses, and clarify the likely cranial nerve and perivascular distribution pathways taken by antibodies to reach the brain from the nasal mucosae.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antibodies; Brain; Intranasal; Olfactory; Perivascular; Trigeminal

Mesh:

Substances:

Year:  2018        PMID: 30081144      PMCID: PMC7234798          DOI: 10.1016/j.jconrel.2018.08.006

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  69 in total

Review 1.  Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery.

Authors:  Mária A Deli
Journal:  Biochim Biophys Acta       Date:  2008-10-17

2.  Vascular permeability to fluorescent protein tracer in trigeminal nerve and gasserian ganglion.

Authors:  B Arvidsson; K Kristensson; Y Olsson
Journal:  Acta Neuropathol       Date:  1973-11-05       Impact factor: 17.088

Review 3.  Revisiting the Mechanisms of CNS Immune Privilege.

Authors:  Antoine Louveau; Tajie H Harris; Jonathan Kipnis
Journal:  Trends Immunol       Date:  2015-10       Impact factor: 16.687

4.  Trafficking and secretion of matrix metalloproteinase-2 in olfactory ensheathing glial cells: A role in cell migration?

Authors:  Yatma Gueye; Lotfi Ferhat; Oualid Sbai; John Bianco; Adlane Ould-Yahoui; Anne Bernard; Eliane Charrat; Jean-Paul Chauvin; Jean-Jacques Risso; François Féron; Santiago Rivera; Michel Khrestchatisky
Journal:  Glia       Date:  2011-02-28       Impact factor: 7.452

Review 5.  Oxytocin-messages via the cerebrospinal fluid: behavioral effects; a review.

Authors:  Jan G Veening; Trynke de Jong; Henk P Barendregt
Journal:  Physiol Behav       Date:  2010-05-20

6.  Anatomical relationships of the pia mater to cerebral blood vessels in man.

Authors:  M Hutchings; R O Weller
Journal:  J Neurosurg       Date:  1986-09       Impact factor: 5.115

7.  Localization of the human neonatal Fc receptor (FcRn) in human nasal epithelium.

Authors:  Sara Heidl; Isabella Ellinger; Verena Niederberger; Eva E Waltl; Renate Fuchs
Journal:  Protoplasma       Date:  2015-12-03       Impact factor: 3.356

8.  Delivery of interferon-beta to the monkey nervous system following intranasal administration.

Authors:  R G Thorne; L R Hanson; T M Ross; D Tung; W H Frey
Journal:  Neuroscience       Date:  2008-01-16       Impact factor: 3.590

9.  Intrathecal antibody distribution in the rat brain: surface diffusion, perivascular transport and osmotic enhancement of delivery.

Authors:  Michelle E Pizzo; Daniel J Wolak; Niyanta N Kumar; Eric Brunette; Christina L Brunnquell; Melanie-Jane Hannocks; N Joan Abbott; M Elizabeth Meyerand; Lydia Sorokin; Danica B Stanimirovic; Robert G Thorne
Journal:  J Physiol       Date:  2017-12-18       Impact factor: 5.182

10.  CSF and blood oxytocin concentration changes following intranasal delivery in macaque.

Authors:  Olga Dal Monte; Pamela L Noble; Janita Turchi; Alex Cummins; Bruno B Averbeck
Journal:  PLoS One       Date:  2014-08-18       Impact factor: 3.240

View more
  22 in total

Review 1.  Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches.

Authors:  Niyanta N Kumar; Michelle E Pizzo; Geetika Nehra; Brynna Wilken-Resman; Sam Boroumand; Robert G Thorne
Journal:  Bioconjug Chem       Date:  2018-10-24       Impact factor: 4.774

Review 2.  Current concepts on communication between the central nervous system and peripheral immunity via lymphatics: what roles do lymphatics play in brain and spinal cord disease pathogenesis?

Authors:  Martin Hsu; Matyas Sandor; Zsuzsanna Fabry
Journal:  Biol Futur       Date:  2021-02-01

3.  Nose-to-Brain Delivery by Nanosuspensions-Based in situ Gel for Breviscapine.

Authors:  Yingchong Chen; Yuling Liu; Jin Xie; Qin Zheng; Pengfei Yue; Liru Chen; Pengyi Hu; Ming Yang
Journal:  Int J Nanomedicine       Date:  2020-12-23

4.  Anatomical basis and physiological role of cerebrospinal fluid transport through the murine cribriform plate.

Authors:  Jordan N Norwood; Qingguang Zhang; David Card; Amanda Craine; Timothy M Ryan; Patrick J Drew
Journal:  Elife       Date:  2019-05-07       Impact factor: 8.713

5.  Apolipoprotein E-Mimetic Peptide COG1410 Enhances Retinal Ganglion Cell Survival by Attenuating Inflammation and Apoptosis Following TONI.

Authors:  Li Kuai; Jianhua Peng; Yong Jiang; Zheng Zheng; Xiyuan Zhou
Journal:  Front Neurosci       Date:  2019-09-13       Impact factor: 4.677

6.  Intranasal administration of a stapled relaxin-3 mimetic has anxiolytic- and antidepressant-like activity in rats.

Authors:  Subhi Marwari; Anders Poulsen; Norrapat Shih; Rajamani Lakshminarayanan; R Manjunatha Kini; Charles William Johannes; Brian William Dymock; Gavin Stewart Dawe
Journal:  Br J Pharmacol       Date:  2019-09-11       Impact factor: 8.739

Review 7.  Neuroinflammation-Driven Lymphangiogenesis in CNS Diseases.

Authors:  Martin Hsu; Collin Laaker; Matyas Sandor; Zsuzsanna Fabry
Journal:  Front Cell Neurosci       Date:  2021-06-23       Impact factor: 6.147

Review 8.  A Review of Hematoma Components Clearance Mechanism After Subarachnoid Hemorrhage.

Authors:  Pengjie Pan; Li Xu; Hongrong Zhang; Yuan Liu; Xiaocheng Lu; Gang Chen; Hailiang Tang; Jiang Wu
Journal:  Front Neurosci       Date:  2020-07-07       Impact factor: 4.677

9.  Therapeutic Effects in a Transient Middle Cerebral Artery Occlusion Rat Model by Nose-To-Brain Delivery of Anti-TNF-Alpha siRNA with Cell-Penetrating Peptide-Modified Polymer Micelles.

Authors:  Takanori Kanazawa; Takumi Kurano; Hisako Ibaraki; Yuuki Takashima; Toyofumi Suzuki; Yasuo Seta
Journal:  Pharmaceutics       Date:  2019-09-15       Impact factor: 6.321

10.  Effects of route of administration on oxytocin-induced changes in regional cerebral blood flow in humans.

Authors:  D A Martins; N Mazibuko; F Zelaya; S Vasilakopoulou; J Loveridge; A Oates; S Maltezos; M Mehta; S Wastling; M Howard; G McAlonan; D Murphy; S C R Williams; A Fotopoulou; U Schuschnig; Y Paloyelis
Journal:  Nat Commun       Date:  2020-03-03       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.